[Use of heptral in the complex treatment of pregnant women with cholestatic liver disease].
In this study it was found out that Heptral has eliminated the main symptoms of cholestasis during the first 2-3 weeks, namely: skin itching, dyspeptic disorder, isteric coloring of skin and mucous membranes. It promotes to stop astenia, insomnia, depression; decreases serum activity of termolabil alcaline phosphates and concentration of bilirubin, cholesterol, lipoprotein; leads to norm the process of lypoproteid metabolism and decreases the liver size (according to the USI results). Heptral treatment results in positive effect which means decreasing frequency of complications, in particular gestosis, ChFPN, pre-term termination of pregnancy and perinatal mortality.


CONCLUSIONS
Heptral is an effective drug for treating pregnant women suffering from ChG, having pathogenetic effect due to multi-sided corrective influence on excretive function of hepatic and biliary channels.
D000328:Adult; D016022:Case-Control Studies; D002780:Cholestasis, Intrahepatic / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*; D011262:Pregnancy Trimester, Second; D011263:Pregnancy Trimester, Third; D012436:S-Adenosylmethionine / Q000627:therapeutic use*
D012436:S-Adenosylmethionine
Primenenie geptrala v kompleksnom lechenii beremennykh s kholestaticheskim gepatozom.